The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of five years of imatinib on cure for patients with advanced GIST: Updated survival results from the prospective randomized phase III BFR14 trial.
François Bertucci
No relevant relationships to disclose
Isabelle Laure Ray-Coquard
Honoraria - Amgen; Merck; Novartis; PharmaMar; Roche; Sanofi
Research Funding - Merck (B); Novartis; Roche
Binh Bui Nguyen
Honoraria - Novartis; PharmaMar
Antoine Adenis
Consultant or Advisory Role - Novartis; Sanofi
Honoraria - Amgen; Bayer; Pfizer; Sanofi
Maria Rios
No relevant relationships to disclose
Florence Duffaud
Consultant or Advisory Role - Merck/MSD
Honoraria - Novartis; Pfizer; PharmaMar; Roche
Didier Cupissol
No relevant relationships to disclose
Christine Chevreau
No relevant relationships to disclose
Emmanuelle Bompas
No relevant relationships to disclose
Julien Domont
No relevant relationships to disclose
Sylvie Chabaud
No relevant relationships to disclose
David Pérol
No relevant relationships to disclose
Jean-Yves Blay
Honoraria - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
Research Funding - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
Axel Le Cesne
Honoraria - Novartis; Pfizer; PharmaMar